raloxifene has been researched along with su 11248 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Lao, K; Li, X; Luo, G; Tang, Z; Xiang, H; You, Q | 1 |
| Cai, X; Li, X; Lin, X; Liu, L; Luo, G; Wu, C; Xiang, H; You, Q | 1 |
1 review(s) available for raloxifene and su 11248
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for raloxifene and su 11248
| Article | Year |
|---|---|
Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Humans; Ligands; MCF-7 Cells; Molecular Structure; Neovascularization, Pathologic; Pyrimidines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Humans; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2019 |